



ELSEVIER

Contents lists available at ScienceDirect

Digestive and Liver Disease

journal homepage: www.elsevier.com/locate/dld

Alimentary Tract

Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts

Maria Cappello^{a,*}, Giovanni Barbara^{b,c}, Massimo Bellini^d, Danilo Consalvo^e, Antonio Di Sabatino^{f,g}, Giovanni Marasco^{b,c}, Mariabeatrice Principi^h, Edoardo Vincenzo Savarino^{i,j}, Annalisa Tortora^k, Laura Obici^l

^a Gastroenterology and Hepatology Section, ProMiSe Department, University of Palermo, Piazza delle Cliniche 2, 90127, Palermo, Italy

^b Department of Medical and Surgical Sciences, University of Bologna, via Massarenti 9, 40138, Bologna, Italy

^c IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138, Bologna, Italy

^d Gastroenterology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Savi 10, 56126, Pisa, Italy

^e Department of Gastroenterology and Digestive Endoscopy, AORN "Antonio Cardarelli", Via Antonio Cardarelli 9, 80131, Napoli, Italy

^f Department of Internal Medicine and Therapeutics, University of Pavia, Piazzale Golgi 19, 27100 Pavia, Italy

^g First Department of Internal Medicine, IRCCS San Matteo Hospital Foundation, Piazzale Golgi 19, 27100 Pavia, Italy

^h Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J), University of Bari, Piazza Umberto I, 70121, Bari, Italy

ⁱ Gastroenterology Unit, Azienda Ospedale Università di Padova, via Nicolò Giustiniani 2, 35100, Padova, Italy

^j Department of Surgery, Oncology and Gastroenterology, University of Padua, via Nicolò Giustiniani 2, 35100, Italy

^k UOC Gastroenterologia, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale L.A. Scuro, 10, 37134 Verona VR, Italy

^l Rare Diseases Unit and Amyloidosis Research and Treatment Centre, IRCCS San Matteo Hospital Foundation, viale Camillo Golgi 19, 27100, Pavia, Italy

ARTICLE INFO

Article history:

Received 26 October 2023

Accepted 23 November 2023

Available online xxx

Keywords:

Gastrointestinal manifestations

Gastroenterologists

Hereditary transthyretin amyloidosis

Patients management

ABSTRACT

Gastrointestinal manifestations are common across all hereditary transthyretin amyloidosis (ATTRv) genotypes. However, they are poorly specific, and their recognition as part of ATTRv is difficult, resulting in misdiagnosis with more common conditions. Moreover, delays in diagnosis occur because of fragmented knowledge, a shortage of centers of excellence and specialists dedicated to ATTRv management, and the scarce involvement of gastroenterologists in multidisciplinary teams. A group of Italian gastroenterologists with experience in the management of ATTRv took part in a project aimed at assessing the awareness of ATTRv among the community of Italian gastroenterologists through an online survey and providing education about practical aspects of ATTRv management. Survey results reported low participation, and very few patients with ATTRv were cared for by gastroenterologists. This highlights the need for greater attention to rare diseases in gastroenterology and emphasizes increasing awareness of ATTRv and diagnostic suspicion. Based on the experts' recommendations, a diagnosis of ATTRv should be suspected when at least one of the 'red flags' is detected. Subsequently, it is suggested to promptly ask for genetic testing and exclude a serum and urinary monoclonal protein, even before the detection of amyloid in biopsy samples, particularly in non-endemic areas.

© 2023 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.

This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

1. Introduction

Hereditary transthyretin amyloidosis (ATTRv, variant) is a rare, rapidly progressive and fatal disease caused by pathogenic variants

* Corresponding author at: Gastroenterology and Hepatology Section, ProMiSe Department, University of Palermo, Palermo, Italy.

E-mail address: marica.cappello61@gmail.com (M. Cappello).

<https://doi.org/10.1016/j.dld.2023.11.025>

1590-8658/© 2023 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Please cite this article as: M. Cappello, G. Barbara, M. Bellini et al., Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts, *Digestive and Liver Disease*, <https://doi.org/10.1016/j.dld.2023.11.025>

per 10,000, with an incidence of 0.003 cases per 10,000/year [6]. Italy represents a non-endemic area for ATTRv with a prevalence of 4.3 per million, with quite variable regional differences [7,8]. The mean age of ATTRv onset in Italy is relatively high (59 years), with only 20 % of patients showing an early onset [7].

Although ATTRv has long been defined as an untreatable disease, in recent years, the therapeutic scenario has changed significantly due to the availability of drugs able to target key molecular events in the process of amyloidogenesis [9–13]. In light of these developments, the correct and timely diagnosis of ATTRv plays a central role in setting up effective therapy, increasing the patient's survival and quality of life, and offering adequate genetic counseling to family members at risk [14,15].

Phenotypes associated with ATTRv can be extremely heterogeneous since the presentation can be predominantly neurologic, predominantly cardiac, or a mix of both depending on the *TTR* variant and other, yet unknown, factors [16]. In most cases, the involvement is often multisystemic [17–20]. In this context, GI manifestations are quite common across all ATTRv genotypes and are most common in patients with neuropathic amyloidosis, in particular those with Val30Met, Glu89Gln, Glu54Gln and Gly47Glu *TTR* mutations [6,21]. In a cross-sectional study from the Transthyretin Amyloidosis Outcomes Survey (THAOS) registry, between 56 and 69 % of patients reported GI disturbances, depending on *TTR* mutation [22]. More recently, results from one single-center Italian study involving patients with ATTRv reported that the prevalence of GI symptoms was 82 % [23].

GI disturbances can present even before the onset of polyneuropathy and are associated with significantly reducing the quality of life [22]. The GI disease course is highly variable, and clinical signs and symptoms are not necessarily related to genotypes and geographic area of origin [24,25].

GI manifestations are poorly specific, and their recognition as part of ATTRv may be difficult, resulting in misdiagnosis with more common conditions with higher epidemiological relevance, such as irritable bowel syndrome (IBS) and functional dyspepsia [26,27]. Moreover, delays in diagnosis may occur because of fragmented knowledge, a shortage of centers of excellence and specialists dedicated to ATTRv disease management, and the scarce involvement of gastroenterologists in multidisciplinary teams [28].

Identification of systemic red flags along with GI disturbances might alert the gastroenterologist to start a diagnostic work-up to confirm or rule out ATTRv. Consequently, promoting awareness among gastroenterologists represents an unmet need to improve patient management, especially in non-endemic areas.

To address these issues, a group of Italian gastroenterologists coordinated by two clinicians with experience in the management of ATTRv took part in a project aimed at assessing the awareness of ATTRv among the community of Italian gastroenterologists and providing education about practical aspects of ATTRv management. This paper discusses the results of this activity, providing practical recommendations on the correct pathway for patient identification, diagnosis and management of GI involvement to improve clinical practice from the gastroenterologist perspective.

2. Methods

A working group composed of two Coordinators with proven expertise in the management of patients with ATTRv and seven Italian gastroenterologists uniformly distributed throughout the Italian territory (Lombardy, Piedmont, Veneto, Emilia Romagna, Tuscany, Lazio, Campania, Puglia, Sicily) took part in this project. All involved gastroenterologists had ≥ 5 years' clinical experience, relevant scientific publications in this field and were regularly involved in speaking activity at national/international congresses. In

the first phase, an online survey was addressed to the Italian gastroenterologist community to assess the global and specific experience in ATTRv patient management. The survey was composed of 26 questions (Appendix I). It was shared through the AIGO (Italian Association of Gastroenterologists and Hospital Digestive Endoscopists) website, newsletter and dedicated emails between November 2022 and April 2023, accounting for about 1300 recipients.

In the second part of the project, the working group analyzed the survey results to define critical clues and provide possible recommendations to fill the emerging gaps. The discussion on key critical topics and practical recommendations was developed based on available literature and consensus among experts to provide educational support to gastroenterologists and healthcare providers operating in this setting.

3. Results

3.1. Awareness on ATTRv among Italian gastroenterologists: survey results

A total of 44 Italian gastroenterologists participated in the survey, most affiliated with university centers ($n=26$; 60%) and working in gastroenterology departments ($n=37$; 84%). Approximately half of these departments ($n=24$) manage about 100–500 patients per month, including patients with IBS, chronic inflammatory bowel diseases (a mean of 100 patients for both conditions), gastroesophageal reflux disease (GERD, a mean of 80 patients) and dyspepsia (a mean of 60 patients). Eleven departments reported to manage more than 500 patients per month.

57% of gastroenterologists ($n=26$) have experience in managing gastroparesis (<40 patients in 92% of cases), mostly patients with diabetic gastroparesis (reported by 36% of participants). 66% ($n=29$) of participants reported experience with chronic idiopathic constipation (<100 patients in 90% of cases) and 84% in managing patients with chronic idiopathic diarrhea (≤ 100 patients in 92% of cases). In the case of patients with unclear etiology related to the above-mentioned conditions, participants were asked if they investigated some systemic symptoms identified based on the literature as related to ATTRv. Among them, the clinical features investigated further were paresthesia/neuropathic pain in most cases (58%), followed by orthostatic hypotension/syncope (47%), asthenia (41%), balance and/or gait disturbances (36%) and dyspnea (25%).

The vast majority of participants were inexperienced in the management of patients with amyloidosis ($n=35$; 81%). Two Departments reported managing 10 patients with amyloidosis without further specification and two patients with wild-type ATTR amyloidosis; other departments reported managing at least one patient with localized gastrointestinal or secondary amyloidosis or light-chain (AL) amyloidosis, respectively.

In 57% of cases, patients were referred to the gastroenterologist by a neurologist and 15% by a cardiologist or a rheumatologist. In 15% of cases, the diagnosis was made directly in the gastroenterology Department.


Five participants (11%) reported experience in the management of ATTRv patients. The main gastroenterological symptoms reported by these participants and their frequency rates are shown in Table 1.

Diagnostic tests most frequently suggested to patients included colonoscopy and esophagogastroduodenoscopy in 80% of cases, blood chemistry and anorectal manometry in 40% of cases, gastric scintigraphy, defecography and CT colonoscopy in 20% of cases. The main prescribed treatments were prokinetics, antidiarrheals, probiotics (80% of cases for each treatment), antibiotics (60%) and laxatives (20%).

Table 1

Gastroenterological symptoms reported by participants with experience in managing patients with ATTRv ($n = 5$).

Symptoms	%
Chronic diarrhea	80
Unintentional weight loss	60
Early satiety	40
Vomiting	40
Chronic constipation	40
Alternation of constipation and diarrhea	20
Dysphagia	20

**Fig. 1.** Red flag symptom clusters suggestive of the diagnosis of ATTRv.

4. Experts recommendations

Based on the survey results, five topics were identified and further investigated through bibliographic research with an educational intent. Topics were: 1) 'red flags' from the gastroenterologist's perspective; 2) the gastroenterological work-up; 3) accuracy in diagnosis; 4) disease-modifying therapies for ATTRv management; and 5) ATTRv monitoring from the gastroenterologist's perspective.

4.1. "Red flags" from the gastroenterologist's perspective

GI symptoms of ATTRv can involve the upper and/or lower GI tract. Upper GI symptoms of gastroparesis, such as early satiety, postprandial fullness, nausea, and vomiting, are common in ATTRv patients due to delayed emptying of contents from the stomach into the small bowel [6]. Gastroparesis in ATTRv is generally attributed to autonomic dysfunction, but the efferent sympathetic and parasympathetic autonomic system's actual role is unclear [21]. Esophageal involvement in ATTRv can rarely lead to dysphagia, even though the prevalence ranges of esophageal involvement from 13% in a radiology study to 22% in an autopsy series, while isolated dysphagia is reported in a few case reports [29]. Indeed, amyloid deposition within the muscularis propria and submucosa could directly impact the Auerbach's and Meissner's plexuses throughout the GI tract, leading to various neurological presentations, such as a dilated and atonic esophagus with diminished peristalsis and narrowing, presenting as a clinical picture similar to achalasia.

Early manifestations of ATTRv may also involve the lower GI tract, presenting as either constipation, alternating constipation/diarrhea or diarrhea, particularly in patients with the early-onset V30M variant [6,22,30]. Diarrhea is the most frequently reported symptom, followed by unintentional weight loss and nausea; fecal incontinence is less frequently reported and mainly occurs in later stages [2,6,31,32]. Other GI disorders that may cause diarrhea, including celiac disease, microscopic colitis or exocrine pancreatic insufficiency, have never been associated with ATTRv to date [21].

Unintentional weight loss, malabsorption of fat and bile acids, and small bowel bacterial overgrowth (SIBO) have also been described in patients with ATTRv, as well as abdominal pain and bloating [31,33,34].

The wide spectrum of GI symptoms in ATTRv patients requires that all gastroenterologists be aware of this potential presentation alone or in combination with signs and symptoms of other organ involvement. Accordingly, some 'red flags' symptoms clusters suggestive for the diagnosis of ATTRv were defined by the working group (Fig. 1), namely: 1) the presence of chronic diarrhea/constipation and/or nausea, vomiting, early satiety (GI symptoms) in concomitance with at least one among bilateral carpal tunnel syndrome, paresthesia, erectile dysfunction, gait and balance disorder, orthostatic hypotension/syncope, neuropathic pain; 2) GI symptoms in concomitance with un-

intentional weight loss, also to distinguish a functional versus organic pathology; 3) GI complaints and symptoms of heart failure/syncope/bradyarrhythmia and an echocardiogram (i.e., increased left ventricular wall thickness, restrictive filling pattern, abnormal left and right ventricular longitudinal strain, and atrial septal thickening) or cardiac magnetic resonance (restrictive morphology, abnormal gadolinium kinetics, and extracellular volume expansion based on T1 mapping) imaging suggesting the possibility of amyloidosis; 4) GI symptoms and a familial history of ATTRv (especially if patient origin from an endemic area). In addition, in the presence of GI symptoms, gastroenterologists must pay attention to muscle weakness, fatigue/dyspnea, bladder dysfunction/recurrent urinary infections and previous biopsies suspecting amyloidosis.

4.2. The gastroenterological work-up

Investigations of upper and lower GI symptoms are recommended to provide diagnosis and to exclude other treatable and reversible diseases (differential diagnosis, further details in the next paragraphs). Examinations may include endoscopy with esophageal biopsies, and if gastroparesis is suspected, a scintigraphy study of gastric emptying can be performed. However, evidence on the role of these examinations in the context of ATTRv is limited [21]. In particular, macroscopic endoscopic findings are usually non-specific for ATTRv, including a fine granular appearance of the mucosa, which may appear as white/yellow elevated/depressed circular areas, and therefore not useful for a definitive diagnosis [35,36]. Anorectal functional disorders must be diagnosed with anorectal manometry, which has not been evaluated in ATTRv patients; thus, abnormal findings are not useful for ATTRv diagnosis [6].

4.3. Reaching an accurate diagnosis

The diagnosis of ATTRv has been traditionally based on the detection of amyloid in biopsy samples [1,37]. However, even if proof of amyloid in a tissue biopsy and typing of fibrils are still the gold standards for optimal diagnosis, it is well-recognized that sensitivity varies according to different biopsy sites (duodenum and the rectum have the highest diagnostic yield) and staining techniques [38]. Moreover, if biopsies are from the GI tract, submucosa should be reached to ensure the diagnosis of ATTRv, even if this procedure might increase the risk of bleeding. Lastly, the proper number of replicates necessary to validate the exam has not been fully elucidated [38].

Considering that correctly identifying the subtype of amyloidosis has important implications for guiding medical management and proper familial counseling, recent studies reported that genetic testing is key to confirming the presence or absence of a mutation in ATTRv and suggested that this test should not be omitted [39]. Indeed, a negative *TTR* gene test for an amyloidogenic variant eliminates a diagnosis of ATTRv. On these bases, it is now recommended to promptly ask for genetic testing and search for a serum and/or urinary monoclonal protein in parallel with the detection

of amyloid in biopsy samples, particularly in non-endemic areas [1,4] (see Supplementary Figure 1 for the suggested diagnostic algorithm).

Bone tracer scintigraphy is now widely accepted for the non-invasive diagnosis of ATTRv (Supplementary Table 1) [4,40]. Cardiac uptake of bone tracers, such as ^{99m}Tc-2,3-dicarboxypropane-1,1-diphosphonate (DPD), ^{99m}Tc-hydroxy methylene diphosphonate (HMDP) or technetium ^{99m}Tc pyrophosphate (PYP), is considered as a substitute for a positive cardiac biopsy [1]. According to the Gillmore criteria, excluding a monoclonal gammopathy by serum and urinary is mandatory to confirm the diagnosis of ATTRv. If the diagnosis of ATTRv is confirmed, TTR genotyping should be performed in all patients to differentiate between wild-type and ATTRv [40].

4.3.1. Differential diagnosis

Upper GI symptoms should be investigated to provide a differential diagnosis with other conditions, such as gastroesophageal reflux and functional and organic dyspepsia. In patients with chronic diarrhea/constipation or alternation of diarrhea and constipation, an accurate dietary and pharmacological history assessment is useful to rule out IBS, constipation or functional diarrhea [41,42]. Some blood chemistry tests (blood count, blood sugar, creatinine PCR, TSH, serological screening for celiac disease, calcemia and fecal calprotectin) are necessary to exclude an organic disease. In the presence of risk factors for organic pathology (age >50 years, family history of colorectal cancer or IBD, weight loss, anemia, etc.), colonoscopy is essential for differentiating ATTRv from colon cancer, colonic obstruction, proctitis and diverticulosis. A fecal calprotectin assessment can be performed if a patient presents with weight loss [43]. In the case of chronic constipation, hypothyroidism should also be taken into account, as well as diabetes mellitus and neurological diseases (e.g., multiple sclerosis, Parkinson's disease). Further, the possible side effects of the patient's medications should be considered [6]. If all those conditions are excluded, ATTRv should be taken into account.

Excluding light-chain (AL) amyloidosis, which is caused by misfolded light chains produced by a small, dangerous B-cell clone, is of fundamental importance since this condition represents a medical emergency and is often clinically indistinguishable from ATTRv on clinical grounds [44]. When a monoclonal protein is identified, amyloid typing by tissue biopsy becomes mandatory.

4.4. ATTRv management

4.4.1. Disease-modifying treatments

Delayed treatment is associated with an accumulating disease burden [45]. Thus, early intervention is fundamental to reducing the risk of developing a significant disability [46]. Increasing knowledge of the molecular mechanisms of the disease has allowed, over the past fifteen years, the progressive development of new targeted therapies [47]. Approved therapeutic strategies presently include gene-silencing agents that suppress hepatic TTR synthesis and TTR stabilizers that prevent the dissociation of circulating TTR tetramers. Moreover, novel therapeutic tools are under investigation to disrupt TTR fibrils [48]. Small interfering RNA (siRNA) or antisense oligonucleotide (ASO) technologies are highly effective in inhibiting liver expression of both mutant and wild-type TTR, significantly suppressing the concentration of the amyloidogenic precursor protein in plasma [47,49]. The siRNA patisiran, vutrisiran and the ASO inotersen have been approved for the treatment of patients with ATTRv polyneuropathy, regardless of the presence and severity of cardiomyopathy [50–52].

Available evidence from clinical trials shows that patients in treatment with patisiran and vutrisiran have a reduced burden of

Table 2

Symptomatic treatment of gastrointestinal manifestations of transthyretin amyloidosis.

Symptoms	Treatment options
Upper gastrointestinal symptoms	Metoclopramide Domperidone Motilin receptor agonists (e.g., erythromycin, clarithromycin) Proton-pump inhibitors Levosulpiride Clebopride Prucalopride Ondansetron* Loperamide
Diarrhea	Racecadotril Cholestyramine + fat-reduced diet Antibiotics (rifaximine or ciprofloxacin/norfloxacin or metronidazole/tinidazole) Octreotide Eluxadolone**
Constipation	Increased fiber intake and bulking agents Polyethylene glycol Sodium picosulphate Bisacodyl Lactulose Lubiprostone Linaclotide Prucalopride Enemas
Malabsorption and Weight loss	Vitamin A, D, E, K supplementation Calcium and magnesium supplementation Vitamin B12 supplementation Infusion of human albumin Enteral or parenteral nutrition Guidance from an experienced Dietician

* This drug can be used for the management of diarrhea.

** Not available in Italy.

autonomic dysfunction and stabilization of nutritional status, suggesting an effect of these treatments on the gastrointestinal autonomic function [51–53]. In particular, in patients treated with patisiran in the APOLLO phase III trial, the modified body mass index (mBMI) was significantly improved after 18 months compared with placebo-treated patients, with an LS mean difference of +115.7 (95% CI: –82.4–149.0), as well as GI symptoms within the GI domain of the COMPASS-31 (–0.8) [51].

For instance, a novel ASO formulation, eplontersen, is under investigation in patients with ATTRv polyneuropathy and cardiomyopathy.

4.4.2. Supportive measures

Treatment of GI symptoms should aim to relieve the disease burden and slow down the progression of GI dysfunction to preserve nutritional status and quality of life. Overall, GI symptoms can be difficult to control, requiring a personalized therapeutic approach that should involve a gradual intervention. Table 2 summarizes the conventional symptomatic supportive measures for upper and lower GI disturbances that can be suggested for managing GI symptoms in ATTRv patients. Nausea and vomiting can be managed mainly with prokinetics; non-pharmacological agents have no demonstrated efficacy in amyloidosis [54,55]. The initial treatment of diarrhea is generally with the opioid-receptor agonist loperamide or with racecadotril, a peripheral enkephalinase inhibitor. If SIBO is suspected or diagnosed, antibiotics can be used intermittently or continuously. In most cases with constipation, dietary changes with increased fiber intake and bulking agents are first-line interventions; however, this may not be sufficient for patients with ATTRv, and pharmacological interventions should be planned. Supplementation is essential if a patient presents with malabsorption and weight loss, preferably early after the onset of diarrhea.

4.5. ATTRv monitoring from the gastroenterologist's perspective

Periodic assessment of the ATTRv disease course is mandatory to adjust therapy, delay clinical deterioration and preserve the patient's quality of life (QoL). The frequency of assessments needs to be adapted to the disease course and the severity and response to treatment. In general, monitoring should be done every 6–12 months. It should comprise blood chemistry tests, BMI evaluation, questionnaires and instrumental tests, always in the context of a neurological and cardiologic re-evaluation.

Nutritional status and patients' reported symptoms represent useful tools to assess and monitor GI involvement in ATTRv [25,45]. Different questionnaires developed for assessing upper GI symptoms, i.e., the Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) and Gastroparesis Cardinal Symptom Index (GCSI), have not been validated in ATTRv [21]. Thus, the compound autonomic dysfunction test (CADT), which scores upper and lower GI symptoms according to their frequency, has been proposed in ATTRv [33]. The Composite Autonomic Symptom Score (COMPASS)-31, composed of 101 items, proved useful for monitoring longitudinally GI manifestations in combination with other autonomic domains in recent trials, such as the registration trial for the siRNA patisiran [11] and vutrisiran [52].

Considering that weight loss is a common symptom of ATTRv amyloidosis, the mBMI, in which the BMI (kg/m^2) is multiplied with serum albumin (g/L) to compensate for edema, can be used to assess the nutritional status and as an indirect evaluation of the GI dysautonomia. mBMI values below $750 \text{ kg}/\text{m}^2\text{g}/\text{L}$ are considered underweight, and values below $600 \text{ kg}/\text{m}^2\text{g}/\text{L}$ suggest severe malnutrition [22]. The product of serum albumin (g/L) and mBMI has been proven useful in measuring disease progression and as a predictor of survival [6]. The mBMI has been shown to correlate with neurological function, including familial amyloid polyneuropathy (FAP) stages and duration of gastrointestinal manifestations [21]. In clinical trials for ATTRv, preservation of mBMI was closely associated with neurological response and improvement in quality of life [21,52].

5. Concluding remarks

With regard to the Italian scenario, 31 different mutations responsible for ATTRv were recorded in a recent epidemiological study and among them, Ile68Leu, Phe64Leu, Val30Met and Glu89Gln were the most reported [7]. In particular, the Val30Met variant was the most common in northern and central Italy, carried by almost one-quarter of patients [7,56]. Otherwise, in southern Italy, Glu89Gln, Phe64Leu were the most frequently reported variants, manifesting with different characteristics with respect to age of onset, phenotype and severity of the disease [7,57]. This significant genotypic heterogeneity is associated with a great variety of presentations, which made ATTRv diagnosis a real challenge in Italy, as in other non-endemic areas.

In this heterogeneous context, GI manifestations are very common and increase with disease duration, negatively impacting nutritional status and patients' survival [6,58]. Thus, gastroenterologists can play a valuable role in the early identification of at-risk patients and the timely management of gastrointestinal symptoms through specific interventions with approved disease-modifying therapies [11,20]. Despite this evidence, a scarce involvement of gastroenterologists in multidisciplinary teams is reported.

In the first phase of this project, an online survey was addressed to the Italian gastroenterologist community to assess the global and specific experience in ATTRv patient management. Obtained results reported low participation in the survey and a very small number of patients with ATTRv cared for by gastroenterologists. This highlights the need for greater attention to rare dis-

eases in gastroenterology and emphasizes the need to implement training programs in this field by scientific societies to increase awareness of ATTRv and diagnostic suspicion. At the same time, a lack of attention from the specialists traditionally considered as a reference for this pathology (e.g., neurologists and cardiologists) towards gastroenterological problems can be suggested. This further highlights the multidisciplinary team's fundamental role in improving the diagnosis of ATTRv and patient management.

Based on the experts' recommendations, a diagnosis of ATTRv should be suspected when at least one of the 'red flags' is detected (Fig. 1). Subsequently, for a definitive diagnosis of ATTRv, it is suggested to promptly ask for genetic testing and exclude a serum and urinary monoclonal protein, even before the detection of amyloid in biopsy samples, in particular in non-endemic areas. This suggested diagnostic approach may overcome the difficulties of biopsy sampling and other invasive diagnostic tests and represents a new opportunity to increase ATTRv diagnosis, which in turn can provide additional reliable data regarding new diagnostic features and peculiar characteristics of this condition.

Conflict of interest

M.C. has served as an invited speaker and advisory board member for Alnylam, Takeda, Janssen, Biogen, Pfizer, and Galapagos.

L.O. has received consultation and speaker fees from Alnylam, Pfizer, Astra Zeneca, Novo Nordisk, BridgeBio and SOBI; M.B. has served as an invited speaker for Aboca, Alnylam, Alfasigma, Diadema, Agave, GE Healthcare.

Author contribution

Maria Cappello: Conceptualization, Methodology, Validation, Writing – original draft, Writing – review & editing. **Giovanni Barbara:** Validation, Writing – review & editing. **Massimo Bellini:** Validation, Writing – review & editing. **Danilo Consalvo:** Validation, Writing – review & editing. **Antonio Di Sabatino:** Validation, Writing – review & editing. **Giovanni Marasco:** Validation, Writing – review & editing. **Mariabatrice Principi:** Validation, Writing – review & editing. **Edoardo Vincenzo Savarino:** Validation, Writing – review & editing. **Annalisa Tortora:** Validation, Writing – review & editing. **Laura Obici:** Conceptualization, Methodology, Validation, Writing – original draft, Writing – review & editing.

Acknowledgements

We wish to thank the Governing Board of Italian Association of Hospital Gastroenterologists (AIGO) for the authorization to diffuse the survey on their official website. Editorial and graphical assistance were provided by Simonetta Papa, PhD, Massimiliano Pianta, and Aashni Shah (Polistudium SRL, Milan, Italy). This assistance was supported by Alnylam.

Funding

There was no explicit funding for this project.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.dld.2023.11.025](https://doi.org/10.1016/j.dld.2023.11.025).

References

- [1] Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. *Nat Rev Neurol* 2019;15(7):387–404.

- [2] Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. *TCRM* 2020;16:109–23.
- [3] Koike H, Katsuno M. Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. *Biomedicines* 2019;7(1):11.
- [4] Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *J Neurol* 2021;268:2109–22.
- [5] Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hoppes M, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy: ATTR-FAP global prevalence. *Muscle Nerve* 2018;57(5):829–37.
- [6] Nakov R, Suhr OB, Ianiro G, Kupcinskas J, Segal JP, Dumitrascu DL, et al. Recommendations for the diagnosis and management of transthyretin amyloidosis with gastrointestinal manifestations. *Eur J Gastroenterol Hepatol* 2021;33(5):613–22.
- [7] Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, Cavallaro T, Chiappini MG, Gemelli C, Pradotto LG, Manganelli F, Leonardi L, My F, Sampaolo S, Briani C, Gentile L, Stancanelli C, Di Buduo E, Pacciolla P, Salvi F, Casagrande S, Bisogni G, Calabrese D, Vanoli F, Di Iorio G, Antonini G, Santoro L, Mauro A, Grandis M, Di Girolamo M, Fabrizi GM, Pareyson D, Sabatelli M, Perfetto F, Rapezzi C, Merlini G, Mazzeo A, Vita G. ATTRv amyloidosis Italian Registry: clinical and epidemiological data. *Amyloid* 2020;27(4):259–65. doi:10.1080/13506129.2020.1794807.
- [8] Cappelli F, Del Franco A, Vergaro G, Mazzoni C, Argirò A, Pieroni M, Giacomini E, Poli S, Allinovi M, Olivetto I, Pieroni F, Scaletti C, Emdin M, Perfetto F. Prevalence of transthyretin-related amyloidosis in Tuscany: data from the regional population-based registry. *Int J Cardiol* 2023 Epub ahead of print. doi:10.1016/j.ijcard.2023.03.063.
- [9] Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med* 2018;379(11):1007–16.
- [10] Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379(1):22–31.
- [11] Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379(1):11–21.
- [12] Spoladore R, Falasconi G, Marcatti M, Di Maio S, Fiore G, Slavich M, et al. Advances in pharmacotherapy for cardiac amyloidosis. *Expert Opin Pharmacother* 2021;22(4):469–81.
- [13] Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy? *Eur J Heart Fail* 2020;22(1):39–53.
- [14] Russo M, Gentile L, Di Stefano V, Di Bella G, Minutoli F, Toscano A, et al. Use of drugs for ATTRv amyloidosis in the real world: how therapy is changing survival in a non-endemic area. *Brain Sci* 2021;11(5):545.
- [15] Grandis M, Obici L, Luigetti M, Briani C, Benedicenti F, Bisogni G, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. *Orphanet J Rare Dis* 2020;15(1):348.
- [16] Adams D, Algalarrondo V, Polydefkis M, Sarswat N, Slama MS, Nativi-Nicolau J. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. *Orphanet J Rare Dis* 2021;16(1):411.
- [17] Pastorelli F, Fabbri G, Rapezzi C, Serenelli M, Plasmati R, Vacchiano V, et al. Neurological involvement in Ile68Leu (p.Ile68Leu) ATTR amyloidosis: not only a cardiogenic mutation. *Amyloid* 2021;28(3):173–81.
- [18] Gentile L, Tourneir I, Amass L, Chapman D, Mazzeo A, the THAOS investigators, et al. Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic loci: update from THAOS. *Cardiol Ther* 2021;10(2):481–90.
- [19] Tini G, Vianello PF, Gemelli C, Grandis M, Canepa M. Amyloid cardiomyopathy in the rare transthyretin Tyr78Phe mutation. *J Cardiovasc Trans Res* 2019;12(6):514–16.
- [20] Dispenzieri A, Coelho T, Conceição I, et al. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. *Orphanet J Rare Dis* 2022;17:236. doi:10.1186/s13023-022-02359-w.
- [21] Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. *Clin Auton Res* 2019;29(S1):55–63.
- [22] Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis-common complications of a rare disease. *Orphanet J Rare Dis* 2014;9:61.
- [23] Luigetti M, Tortora A, Romano A, Di Paolantonio A, Guglielmino V, Bisogni G, Gasbarrini A, Calabresi P, Sabatelli M. Gastrointestinal manifestations in hereditary transthyretin amyloidosis: a single-centre experience. *J Gastrointest Liver Dis* 2020;29(3):339–43. doi:10.15403/jgld-2474.
- [24] Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. *J Peripher Nerv Syst* 2016;21:5–9.
- [25] Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. *Curr Opin Neurol* 2016;29(S1):S14–26.
- [26] Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol* 2012;10 712–721.e4.
- [27] Talley NJ. Functional dyspepsia: advances in diagnosis and therapy. *Gut Liver* 2017;11:349–57.
- [28] Nakov R, Sarafov S, Gospodinova M, Kirov A, Chamova T, Todorov T, et al. Transthyretin amyloidosis: testing strategies and model for center of excellence support. *Clin Chim Acta* 2020;509:228–34.
- [29] Ailawadi S, Cheema BK, Salahuddin S, Agrawal S. A rare case of gastrointestinal amyloidosis presenting as dysphagia. *Cureus [Internet]* 10 febbraio 2022. [citato 12 maggio 2023]; Disponibile su: <https://www.cureus.com/articles/84475-a-rare-case-of-gastrointestinal-amyloidosis-presenting-as-dysphagia>.
- [30] Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. *Muscle Nerve* 2007;35(1):116–18.
- [31] Nakov R, Sarafov S, Nakov V, Gospodinova M, Todorov T, Kirov A, et al. Gastrointestinal manifestations in hereditary transthyretin amyloidosis associated with Glu89Gln mutation. *JGLD* 2019;28(4):421–6.
- [32] Toppeta A, Dell'Era A, Mantia B, Molteni P, Pellegrinelli A, Marceca A, Ardizzone ST. 09.8 From bowel ultrasound to a diagnosis of hereditary transthyretin amyloidosis. *Dig Liver Dis* 2023;55(Supplement 2):S176–7.
- [33] Wixner J, Suhr OB, Anan I. Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single center experience over 40 years. *Expert Rev Gastroenterol Hepatol* 2018;12(1):73–81.
- [34] Marberg T, Karling P, Söderberg K, Anan I, Wixner J. Self-reported gastrointestinal symptoms are more common in liver transplanted transthyretin amyloidosis patients than in healthy controls and in patients transplanted for end-stage liver disease. *Amyloid* 2019;26:47–8.
- [35] Hokama A. Endoscopic and histopathological features of gastrointestinal amyloidosis. *WJGE* 2011;3(8):157.
- [36] Lin XY, Pan D, Sang LX, Chang B. Primary localized gastric amyloidosis: a scoping review of the literature from clinical presentations to prognosis. *World J Gastroenterol* 2021;27(12):1132–48.
- [37] Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis. *Cardiol Ther* 2021;10(2):289–311.
- [38] Iida T, Yamano H, Nakase H. Systemic amyloidosis with gastrointestinal involvement: diagnosis from endoscopic and histological views. *J Gastroenterol Hepatol* 2018;33(3):583–90.
- [39] Brown EE, Lee YZ, Halushka MK, Steenbergen C, Johnson NM, Almansa J, et al. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. *Amyloid* 2017;24(2):92–5.
- [40] Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation* 2016;133(24):2404–12.
- [41] Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, Falangone F, Fucci L, Galeazzi F, Iovino P, Sarnelli G, Savarino E, Stanghellini V, Staiano A, Stasi C, Tosetti C, Turco R, Ubaldi E, Zagari RM, Zenzeri L, Marasco G. Italian guidelines for the management of irritable bowel syndrome: joint consensus from the Italian Societies of Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). *Dig Liver Dis* 2023;55(2):187–207.
- [42] Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrón M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Functional bowel disorders with diarrhoea: clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. *United European Gastroenterol J* 2022;10(6):556–84.
- [43] Nakov R, Sarafov S, Nakov V, Gospodinova M, Ianiro G, Todorov T, et al. Fecal calprotectin levels are elevated in transthyretin amyloidosis patients with gastrointestinal manifestations. *Medicine* 2020;99(11):e19509.
- [44] Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. *Hematol Am Soc Hematol Educ Program* 2017;2017(1):1–12.
- [45] Gonzalez-Duarte A. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). *Clin Auton Res* 2019;29(2):245–51.
- [46] Obici L, Adams D. Acquired and inherited amyloidosis: knowledge driving patients' care. *J Peripher Nerv Syst* 2020;25(2):85–101.
- [47] Aimò A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. *Nat Rev Cardiol* 2022;19(10):655–67.
- [48] Magrinelli F, Fabrizi GM, Santoro L, Manganelli F, Zanette G, Cavallaro T, et al. Pharmacological treatment for familial amyloid polyneuropathy. *Cochrane Neuromuscular Group, curatore. Cochrane Database System Rev [Internet]* 20 aprile 2020. [citato 12 maggio 2023]; Disponibile su: <https://doi.wiley.com/10.1002/14651858.CD012395.pub2>.
- [49] Yu AM, Choi YH, Tu MJ. RNA Drugs and RNA targets for small molecules: principles, progress, and challenges. *Touyz RM, curatore. Pharmacol Rev* 2020;72(4):862–98.
- [50] Tsoi MR, Lin JH, Patel AR. Emerging therapies for transthyretin amyloidosis. *Curr Oncol Rep* 2023;25(6):549–58.
- [51] González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. *J Neurol* 2020;267(3):703–12.
- [52] Obici L, Ajroud-Driss S, Lin KP, Berk JL, Gillmore JD, Kale P, Koike H, Danese D, Aldinc E, Chen C, Vest J, Adams D, HELIOS-A Collaborators Study Group. Impact of vutrisiran on quality of life and physical function in patients with hered-

- itary transthyretin-mediated amyloidosis with polyneuropathy. *Neurol Ther* 2023;12(5):1759–75. doi:10.1007/s40120-023-00522-4.
- [53] Conceição I. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. *Clin Auton Res* 2019;29(Suppl 1):11–17.
- [54] Camilleri M, Kuo B, Nguyen L, Vaughn VM, Petrey J, Greer K, et al. ACG clinical guideline: gastroparesis. *Am J Gastroenterol* 2022;117(8):1197–1220.
- [55] Schol J, Wauters L, Dickman R, Drug V, Mulak A, Serra J, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. *United European Gastroenterol J* 2021;9(3):287–306.
- [56] Parman Y, Adams D, Obici L, European Network for TTR-FAP (ATTReuNET), et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. *Curr Opin Neurol* 2016;29(Suppl 1(Suppl 1)):S3–S13.
- [57] Mazzeo A, Russo M, Di Bella G, et al. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. *J Neuromuscul Dis* 2015;2(s2):S39–48.
- [58] Brinch D, Di Stefano V, Muscarella S, Carrozza L, Saladino M, Crispino F, et al. OC.06.4 Gastrointestinal involvement in hereditary transthyretin amyloidosis: the role of gastroenterologists in early diagnosis of a progressive but now potentially curable disease. *Dig Liver Dis* 2022;54:S83.